Dated : 19th May 2009
IntelGenx Corp. and Circ Pharma to Commence Phase 1 Proof-of-Concept Study of CRES Pravastatin, a Novel Low Dose Formulation Containing Pravastatin for the Treatment of Hyperlipidemia
SAINT LAURENT, QUEBEC and DUBLIN, IRELAND, May 19, 2009 (Marketwire via COMTEX) -- IntelGenx Corp. (IGX)(US:IGXT) ("IntelGenx") and Circ Pharma ("Circ"), announced today that they completed the formulation development of CRES Pravastatin (Controlled Release Enhanced Statin), and will enter the clinical development phase in Q2/2009 to initiate the proof-of-concept programme. This Phase 1 trial is a randomized, single dose, crossover study comparing CRES Pravastatin to conventional Pravachol tablets in normal healthy volunteers. The primary objective of this trial is to evaluate the pharmacokinetics of CRES Pravastatin versus conventional Pravachol tablets.Read more...
Dated : 4th May 2009
Circ Pharma Limited enters into Development Agreement for Chrono Tramadol with Elan Corporation Plc
Dublin, Ireland, May 2009 - Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain.Read more...
Dated : 19th January 2009
IntelGenx Corp. and Circ Pharma Ltd announced today a partnership to develop and commercialise a novel drug for the treatment of hyperlipidemia.Saint Laurent, Quebec, and Dublin, Ireland - Jan. 19, 2009 - IntelGenx Corporation (OTCBB:IGXT, TSXV:IGX)("IntelGenx") and Circ Pharma ("Circ") today announced a partnership in which IntelGenx will formulate, manufacture and supply to Circ, and Circ will develop and commercialise, a novel drug product for the treatment of hyperlipidemia...
Read more...
Dated : 27th October 2006
Appointment of management team, acquisition of assets and initial funding.Read more...